SCISIPBIO: Collaborative: Financing the Biomedical Research Enterprise

SCISIPBIO：协作：为生物医学研究企业融资

基本信息

批准号：
1935023
负责人：
Alexandra Graddy-Reed
金额：
$ 28.37万
依托单位：
University of Southern California
依托单位国家：
美国
项目类别：
Standard Grant
财政年份：
2019
资助国家：
美国
起止时间：
2019-12-15 至 2024-11-30
项目状态：
已结题

来源：
https://www.nsf.gov/awardsearch/showAward?AWD_ID=1935023&HistoricalAwards=false
关键词：
SCISIPBIO Collaborative Financing Biomedical Research

项目摘要

The scientific workforce is at the core of the biomedical industry and their research provides the basis for public benefits in the identification of diseases and in the discovery of treatments and cures. Realizing these life-saving benefits involves investment and collaboration between pharmaceutical and biotech companies, government funding agencies, and nonprofit organizations. Yet each funder has varying objectives that reflect their changing priorities and have the potential to affect the research conducted. While the federal government has traditionally funded basic research, the National Institutes of Health (NIH), the largest federal funder of academic biomedical research, has increasingly emphasized translational research. Industry funding of academic research, while remaining at steady levels, often comes with secrecy requirements that have the potential to impede broad technological advances. Further, both federal and industry funders have become more risk averse in their investments, exacerbating a funding gap between invention and commercialization. In response, philanthropic funding--donations and investments made by nonprofit organizations such as private foundations--is increasing. Philanthropic funders are experimenting with new models to catalyze collaborations across players at different points in the drug development process. This project assesses how these different funders and their varying strategies spur biomedical innovation so that future investments can be optimized for society's benefit. In addition, this project examines how a funder's strategy impacts the type of research conducted between basic, translational, and applied, as well as how it affects a scientist's career path. The funding landscape of biomedical research is changing with federal funding in flux, industry funding growing more risk-averse, and nonprofit funding on the rise but employing different terms of sponsored research agreements. To better understand the differences in how these funding strategies are implemented and their subsequent impact on innovation, this project builds an extensive scientist-level database of biomedical projects and outcomes. The database uses university administrative records to merge together individual data with sponsored-research proposals and awards, as well as scientific outcomes. Outcomes include peer-reviewed publication activity and technology transfer data on inventions, disclosures, and spin-out firms. Using econometric analysis, these data are used to assess how different funder's strategies impact biomedical innovation, the pipeline of science studied by academics, and the impacts of these choices on the scientists' careers.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

科学劳动力是生物医学行业的核心，他们的研究为鉴定疾病和疗法和治疗方法的公共利益提供了基础。实现这些挽救生命的好处涉及制药公司和生物技术公司，政府资助机构和非营利组织之间的投资和合作。然而，每个资助人都有不同的目标，可以反映其优先事项的变化，并有可能影响所进行的研究。尽管联邦政府传统上为基础研究提供了资助，但美国国立卫生研究院（NIH）是学术生物医学研究的最大资助者，越来越强调转化研究。学术研究的行业资金虽然保持稳定，但通常会带来秘密要求，这些要求有可能阻碍广泛的技术进步。此外，联邦和行业的资助者在投资方面都变得更加风险，加剧了发明和商业化之间的资金差距。作为回应，非营利组织（例如私人基金会）进行的慈善资金和投资正在增加。慈善资助者正在尝试新模型，以催化药物开发过程中不同地点的参与者的合作。该项目评估了这些不同的资助者及其不同策略如何刺激生物医学创新，从而可以为社会的利益进行优化未来的投资。此外，该项目研究了资助者的策略如何影响基本，翻译和应用之间进行的研究类型，以及它如何影响科学家的职业道路。生物医学研究的资金格局正在发生变化，因为联邦资金用于助焊剂，行业资金越来越大，规避风险的资金和非营利性资金随着赞助的研究协议而增加。为了更好地了解这些资金策略的实施及其随后对创新的影响的差异，该项目建立了广泛的科学家级生物医学项目和成果数据库。该数据库使用大学行政记录将个人数据与赞助研究的建议和奖项以及科学成果合并在一起。成果包括经过同行评审的出版活动和技术传输数据，有关发明，披露和纺纱公司的数据。使用计量经济学分析，这些数据用于评估不同的资助者的策略如何影响生物医学创新，学者研究的科学渠道以及这些选择对科学家职业的影响。该奖项反映了NSF的法定任务，并通过使用该基金会的知识分子优点和广泛的范围来评估NSF的法定任务，并被认为是值得的支持。